Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
Fernandez-Rodriguez L, Cianciaruso C, Bill R, Trefny MP, Klar R, Kirchhammer N, Buchi M, Festag J, Michel S, Kohler RH, Jones E, Maaske A, Vom Berg J, Kobold S, Kashyap AS, Jaschinski F, Dixon KO, Pittet MJ, Zippelius A.
Fernandez-Rodriguez L, et al. Among authors: kobold s.
J Immunother Cancer. 2023 May;11(5):e006714. doi: 10.1136/jitc-2023-006714.
J Immunother Cancer. 2023.
PMID: 37208130
Free PMC article.